T he interest level among practitioners and investigators alike in linking vitamin D deficiency with cardiovascular outcomes has hardly subsided, despite the consistent lack of clear evidence supporting the relationship. Why does there continue to be such feverish interest in the subject matter? Despite our best efforts during the past half century to understand and modify known risk factors, cardiovascular disease remains one of the most common causes of death among women and men worldwide. 1 The major outcomes of interest, such as myocardial infarction and stroke, have substantial morbidity, and the number of individuals newly affected by these conditions is not likely to diminish. As with the outcomes, the exposure of interest is easily quantified although with various cut points that constitute normal and abnormal levels. Circulating levels of 25 hydroxyvitamin D (25OHD), unlike biomarkers for most other vitamins, can be measured routinely using widely accessible automated platforms. Global population studies would argue that vitamin D deficiency has reached almost epidemic proportions. 2 Furthermore, and most importantly, correcting vitamin D deficiency is not only possible (and quantifiable) but also fairly inexpensive. Finally, experimental studies strongly suggest a myriad of biological pathways linking cardiovascular disease and vitamin D deficiency, thus supporting the plausibility that treatment with vitamin D would improve cardiac structure, prevent plaque development, and lower blood pressure, among a host of other cardiovascular-related end points. [3] [4] [5] [6] [7] [8] The combination of these and possibly other factors have fueled the perfect storm, yet studies attempting to establish a causal relationship between vitamin D and cardiovascular disease are unlikely to be completed soon. 9
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Defining the level of circulating 25OHD below which replacement is necessary continues to be debated 10 ; however, most would agree that total 25OHD levels <10 ng/mL constitute profound vitamin D deficiency. 7 Thresholds to define vitamin D deficiency have been derived largely from studies on bone health and enjoy ample supportive data, in contrast to the paucity of data related to vitamin D supplementation and cardiovascular disease. 11 We can learn important lessons about studying vitamin deficiency and outcomes from Sommer, 12 the Albert Lasker Award for Clinical Research recipient in 1997, who reminded us that to effectively study the consequences of vitamin A deficiency, outcome studies had to be performed in populations that were truly vitamin A deficient. For vitamin D, in addition to studying those who are deficient, we also have the opportunity to test whether any benefit is conferred with supplementation above the recommended dietary allowance.
Two studies appearing in this issue of Arteriosclerosis, Thrombosis, and Vascular Biology highlight that baseline serum levels of 25OHD are not associated with the presence or progression of carotid intima-media thickness (IMT) or plaque burden. Although past studies have addressed this important topic, these 2 well-conducted cohort studies represent large diverse populations living in different continents, yet they reach similar conclusions.
In the study by Blondon et al, 13 >3000 individuals in the Multi-Ethnic Study of Atherosclerosis were followed up for ≈9 years. Baseline blood levels of 25OHD and parathyroid hormone (PTH) were examined for cross-sectional and longitudinal relationships with baseline and follow-up measures of carotid IMT and burden of carotid plaques. 25OHD levels were divided into 3 groups, the lowest category having levels <20 ng/mL. Those with the highest blood PTH displayed levels ≥65 pg/mL. Not surprisingly, black subjects constituted the largest proportion of individuals with the lowest levels of 25OHD and the highest levels of PTH. Several models were explored and excellent sensitivity analyses were conducted, yet overall no association with baseline or follow-up carotid IMT or carotid plaque burden was found with either baseline 25OHD or PTH. Regardless of the potentially skewed distributions of PTH levels and potential challenges of determining which variables to include the models, their methods seem sound and analyses robust for an unequivocally null effect.
In the study by Deleskog et al 14 of >3000 subjects recruited from 5 European countries, baseline serum 25OHD was not correlated with baseline, 15-, or 30-month measures of carotid IMT and plaque area. Baseline 25OHD was associated minimally with one baseline measure of carotid IMT (mean common carotid IMT), but not with baseline plaque area. Similarly, there was no significant association between baseline 25OHD level and progression of either carotid IMT or plaque area. Selection of variables for multivariable analyses was based on the Bayesian information criterion, which may have excluded clinically important variables. Nevertheless, the authors conclude that there is likely no major causal protective involvement of vitamin D in early subclinical atherosclerosis. In the context of past studies that have been largely conflicting, the
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November 2013 authors conclude that only interventional studies can finally put this question to rest. Collectively, these cohort studies included >6700 individuals. Both studies used baseline levels of 25OHD to correlate with subclinical measures of atherosclerosis. Single time point measurements can, indeed, lend themselves to misclassification of the exposure, especially when the outcomes are several years removed, and intervening therapies and lifestyle changes may also have altered the outcomes. Developing appropriate multivariable models in such longitudinal studies also can be a challenge: certain variables included in the regression models may have been linked with vitamin D status, thereby potentially concealing important effects of vitamin D status. These include measures of physical activity, body mass index, lipid status, and blood pressure, all of which have been linked with vitamin D status, and all of which are robustly linked with cardiovascular outcomes. Thus, it is important to control for potential confounding effects of these variables.
Were the exposures and outcomes appropriate in these 2 studies? First, is carotid IMT a potential surrogate for cardiovascular events? The strength of carotid IMT as a surrogate continues to be debated; most studies conclude that baseline measures of carotid IMT are linked to cardiovascular events, yet progression of carotid IMT is not. 15, 16 Furthermore, standard measures of carotid IMT progression in the cohort examined by Deleskog et al do not correlate with future cardiovascular events in this particular cohort. 17 Second, did these studies actually include patients who were vitamin D deficient? In the study by Blondon et al, 13 those classified as having the lowest levels of 25OHD were predominantly black subjects. In the United States, blacks tend to have the lowest levels of total 25OHD; this group also enjoys the highest measures of bone mineral density and the lowest risk for bone fractures, both of which have traditionally been tightly linked with vitamin D deficiency. 18, 19 Recent data would suggest, however, that blacks are perhaps not deficient when one examines bioavailable vitamin D levels. 20 In the study by Deleskog et al, 14 only 8% of subjects were categorized as vitamin D deficient (serum levels <25 nmol/L) at baseline. Therefore, it is unclear whether these 2 studies included a large enough population with true vitamin D deficiency. The absence of true vitamin D deficiency may have limited their likelihood of uncovering an association, assuming a nonlinear relationship and the likely presence of a threshold effect.
Should inconsistent and, at times, null associations in observational studies assuage our interest in performing large randomized trials? Several randomized trials have examined the effect of vitamin D on cardiovascular outcomes; however, most conclusions drawn from such studies are limited given that they were not designed to specifically test cardiovascular endpoints, vitamin D dosing may not have been optimized, or confounding factors such as coadministration of calcium were present. 21 Even in the context of acknowledging publication bias, there exists strong and ever growing biological support linking vitamin D with critical pathways leading to cardiovascular disease. In fact, several (but not all) human studies continue to be supportive. 22, 23 Finally, nutritional intervention, if beneficial, is inexpensive and can be obtained easily by persons worldwide. Would we have been more convinced if the observational studies were convincingly positive? We are reminded that even in such a setting directed interventions can fail to close the loop. 24 Therefore, before we turn out the lights, it seems prudent to await the results of some of the largest and most comprehensive clinical trials in the area, which are underway in the United States 9 and abroad.
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